Biotechnology

What Is Epigenetics?

Epigenetics is the study of chemical marks on DNA and its packaging that switch genes on or off without changing the DNA sequence. Faulty epigenetic control contributes to cancer and other diseases, and several approved drugs target it.

Key points

  • Epigenetic marks change how genes are used without altering the DNA sequence itself.
  • The two best-studied marks are DNA methylation, which attaches methyl groups to DNA, and histone modification, which changes how tightly DNA is packaged.
  • Epigenetic patterns are what make cell types different from one another, and they can change with development, environment, and disease.
  • Epigenetic drugs are already approved: the FDA approved azacitidine for myelodysplastic syndrome subtypes on May 19, 2004, and the histone deacetylase inhibitor vorinostat on October 6, 2006.
  • The Roadmap Epigenomics Consortium published 111 reference human epigenomes in 2015 to map these marks across cell types.

If the genome is a set of instructions, epigenetics determines which instructions each cell actually reads. Epigenetic marks are chemical tags on DNA and on the proteins that package it. They switch genes on or off without changing the DNA sequence. They explain how cells with identical DNA become skin, nerve, or blood cells, and how that control can go wrong in disease.

The definition

The prefix epi- means "on top of" or "above." Epigenetics is the study of changes in gene activity that do not involve changes to the DNA sequence. The complete set of these marks across the genome is the epigenome. The National Human Genome Research Institute describes the epigenome as a multitude of chemical compounds that can tell the genome what to do.

The main epigenetic marks

DNA methylation

In DNA methylation, proteins attach small chemical tags called methyl groups to specific places on the DNA. According to NHGRI, these tags turn genes on or off by affecting how the DNA interacts with other proteins, which lets cells "remember" which genes should be on or off. Heavy methylation near a gene typically silences it.

Histone modification

DNA in cells is wrapped around spool-like proteins called histones. Chemical tags added to histones change how tightly the DNA is wound:

  • Tightly packed DNA is hard for the cell's machinery to reach, so genes there tend to be switched off.
  • Loosely packed DNA is accessible, so genes there can be switched on.

Other layers

Cells also use certain RNA molecules and the three-dimensional folding of chromosomes to regulate genes. Together these systems form a control layer on top of the genetic code.

Why epigenetics matters

Area Role of epigenetics
Development Establishes and maintains different cell types from the same genome
Cell memory Keeps genes on or off as cells divide
Environment Some marks respond to factors such as diet, smoking, and stress
Aging Methylation patterns change predictably with age
Disease Faulty marks can silence protective genes or activate harmful ones, especially in cancer

Epigenetic marks are generally more changeable than DNA sequence. That is part of what makes them interesting as drug targets: unlike most mutations, they can in principle be reversed.

Mapping the epigenome

In 2015, the Roadmap Epigenomics Consortium published 111 reference human epigenomes in Nature, mapping DNA methylation, histone modifications, and DNA accessibility across a wide range of human cell types and tissues. Such maps help researchers interpret genetic variants that fall outside genes: many disease-linked variants sit in regulatory regions whose activity is marked epigenetically in specific cell types.

Epigenetics in drug development

Approved epigenetic drugs

Several approved drugs work by changing epigenetic marks, mostly in blood cancers:

Drug class How it works Example and FDA approval
Hypomethylating agents Reduce DNA methylation, reactivating silenced genes Azacitidine, approved May 19, 2004 for subtypes of myelodysplastic syndrome
Histone deacetylase (HDAC) inhibitors Block enzymes that remove certain histone tags, loosening DNA packaging Vorinostat, approved October 6, 2006 for cutaneous manifestations of cutaneous T-cell lymphoma

Dates from FDA approval summaries published by FDA reviewers (Kaminskas et al., 2005; Mann et al., 2007).

In the controlled trial supporting azacitidine's approval, the overall response rate was 15.7% with azacitidine, and no patients in the observation group responded. Vorinostat's approval was based on a single-arm Phase 2 trial in 74 patients whose disease had progressed after two earlier systemic therapies.

Current research directions

  • Next-generation epigenetic inhibitors that target specific enzymes that write, erase, or read epigenetic marks.
  • Epigenetic editing, which uses tools derived from CRISPR to change marks at a single gene without cutting the DNA.
  • Epigenetic biomarkers, such as methylation patterns in blood that may help detect cancer early or estimate biological age.

Limitations and caution

  • Cause or consequence? Epigenetic changes seen in disease may be a result of the disease rather than its cause.
  • Cell-type specificity. Marks differ between cell types, so measurements in blood may not reflect what happens in the brain or liver.
  • Broad drug effects. First-generation epigenetic drugs affect marks across the whole genome, not just at disease-relevant genes, which contributes to their side effects.
  • Overstated claims. Popular coverage often exaggerates how much lifestyle can "reprogram" genes. Most epigenetic research in humans shows associations, and evidence for specific health interventions is limited.

Sources

  1. National Human Genome Research Institute. Epigenomics Fact Sheet.Regulator
  2. Roadmap Epigenomics Consortium. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317–330.Peer-reviewed
  3. Kaminskas E, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical Cancer Research. 2005;11(10):3604–3608.Peer-reviewed
  4. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist. 2007;12(10):1247–1252.Peer-reviewed
  5. MedlinePlus Genetics (National Library of Medicine). What is a gene variant and how do variants occur?Regulator

This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.